Backgound: The tumor necrosis factor alpha (TNF-α) might play a central role in insulin resistance, a frequent correlate of obesity likely contributing to some obesity-associated complications. Adult growth hormone (GH) deficiency syndrome (GHDA) shares with obesity excessive fat mass, hyperlipidemia, increased cardiovascular risk, and insulin resistance. On the other hand, GH has been shown to induce transient deterioration of glucose metabolism and insulin resistance when administered in normal humans and in GHDA patients. No information is presently available on the relationship between serum TNF-α levels and insulin sensitivity in GHDA. Methods: We compared the serum TNF-α levels found in 10 GHDA patients before and after a 6-month recombinant human GH therapy (Genotropin), in an insulin resistance prone population of 16 obese (OB) patients and in 38 normal-weight healthy blood donors (controls). The insulin sensitivity was assessed by a euglycemic-hyperinsulinemic glucose clamp in all the GHDA patients and in 10 OB and in 6 control subjects. Results: The serum TNF-α levels were not significantly different in OB patients (42.2 ± 12.81 pg/ml), in GHDA patients at baseline (71.3 ± 23.97 pg/ml), and in controls (55.3 ± 14.28 pg/ml). A slight decrease of TNF-α values was noted in GHDA patients after 6 months of recombinant human GH treatment (44.5 ± 20.19 pg/ml; NS vs. baseline). The insulin sensitivity (M) was significantly reduced in OB patients (2.4 ± 0.30 mg/kg/min) as compared with control subjects (7.5 ± 0.39 mg/kg/min) and in GHDA patients both at baseline (6.6 ± 0.6 mg/kg/min) and after recombinant human GH therapy (5.6 ± 0.7 mg/kg/min). The insulin sensitivity in the GHDA patients, similar to that of controls at baseline, worsened after recombinant human GH treatment (p < 0.05 vs. baseline; p = 0.05 vs. controls). Linear regression analysis showed no correlation between TNF-α and M values (see text) in all patient groups. Conclusions: These data indicate that circulating concentrations of TNF-α do not reflect the degree of insulin resistance in obesity and GHDA. They, however, do not exclude that TNF-α may induce insulin resistance at tissue level. Copyright

The serum concentration of tumor necrosis factor alpha is not an index of growth hormone- or obesity-induced insulin resistance / A.I. Pincelli, A. Brunani, M. Scacchi, A. Dubini, R. Borsotti, A. Tibaldi, L. Pasqualinotto, E. Maestri, F. Cavagnini. - In: HORMONE RESEARCH. - ISSN 0301-0163. - 55:2(2001), pp. 57-64.

The serum concentration of tumor necrosis factor alpha is not an index of growth hormone- or obesity-induced insulin resistance

M. Scacchi;
2001

Abstract

Backgound: The tumor necrosis factor alpha (TNF-α) might play a central role in insulin resistance, a frequent correlate of obesity likely contributing to some obesity-associated complications. Adult growth hormone (GH) deficiency syndrome (GHDA) shares with obesity excessive fat mass, hyperlipidemia, increased cardiovascular risk, and insulin resistance. On the other hand, GH has been shown to induce transient deterioration of glucose metabolism and insulin resistance when administered in normal humans and in GHDA patients. No information is presently available on the relationship between serum TNF-α levels and insulin sensitivity in GHDA. Methods: We compared the serum TNF-α levels found in 10 GHDA patients before and after a 6-month recombinant human GH therapy (Genotropin), in an insulin resistance prone population of 16 obese (OB) patients and in 38 normal-weight healthy blood donors (controls). The insulin sensitivity was assessed by a euglycemic-hyperinsulinemic glucose clamp in all the GHDA patients and in 10 OB and in 6 control subjects. Results: The serum TNF-α levels were not significantly different in OB patients (42.2 ± 12.81 pg/ml), in GHDA patients at baseline (71.3 ± 23.97 pg/ml), and in controls (55.3 ± 14.28 pg/ml). A slight decrease of TNF-α values was noted in GHDA patients after 6 months of recombinant human GH treatment (44.5 ± 20.19 pg/ml; NS vs. baseline). The insulin sensitivity (M) was significantly reduced in OB patients (2.4 ± 0.30 mg/kg/min) as compared with control subjects (7.5 ± 0.39 mg/kg/min) and in GHDA patients both at baseline (6.6 ± 0.6 mg/kg/min) and after recombinant human GH therapy (5.6 ± 0.7 mg/kg/min). The insulin sensitivity in the GHDA patients, similar to that of controls at baseline, worsened after recombinant human GH treatment (p < 0.05 vs. baseline; p = 0.05 vs. controls). Linear regression analysis showed no correlation between TNF-α and M values (see text) in all patient groups. Conclusions: These data indicate that circulating concentrations of TNF-α do not reflect the degree of insulin resistance in obesity and GHDA. They, however, do not exclude that TNF-α may induce insulin resistance at tissue level. Copyright
Settore MED/13 - Endocrinologia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/176114
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 8
social impact